adMare
News

News - Thumbnail

September 25 2023

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

– ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes –

– ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies –

Read
News - Thumbnail

August 25 2023

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.

Read
News - Thumbnail

August 24 2023

adMare BioInnovations invites early-career science professionals to apply to the BioInnovation Scientist (BIS) Program: Foundations Cohort II

 

Read
News - Thumbnail

August 15 2023

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

 

Read
News - Thumbnail

August 10 2023

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

 

Read
News - Thumbnail

July 24 2023

Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.

Read
News - Thumbnail

July 17 2023

Landmark Report Published on the Status of Inclusion, Diversity, Equity and Accessibility (IDEA) in Canada’s Life Sciences Sector

 

Read
News - Thumbnail

July 05 2023

Abdera’s Success: adMare model of company creation 

 

Read
News - Thumbnail

July 04 2023

CPDC Funds Research at Simon Fraser University for Developing
an LAT1-targeting Pet Tracer for Imaging Cancer
 

Read
News - Thumbnail

July 04 2023

Applications Now Open for Cohort VI of the adMare Academy Executive Institute Program

 

Read
News - Thumbnail

June 29 2023

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies

 

Read
News - Thumbnail

June 15 2023

Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023 

 

Read
1 2 3 4 5 6 7 8 9